Novel combination of drugs may overcome drug-resistant cancer cells

Cancer cells can adapt and develop resistance to chemotherapy drugs, making it difficult to eradicate tumors. A new study led by investigators from Brigham and Women’s Hospital suggests that a combination of three drugs, including a new class of glucose-6-phosphate dehydrogenase inhibitors, could overcome cross-therapy resistance. The results of the…

AI reveals new breast cancer types that respond differently to treatment: Revelations could personalize treatment, including picking out those likely to benefit from immunotherapy

Scientists have used artificial intelligence to recognise patterns in breast cancer — and uncovered five new types of the disease each matched to different personalised treatments. Their study applied AI and machine learning to gene sequences and molecular data from breast tumours, to reveal crucial differences among cancers that had…

Lymphoma trial finds combination targeted therapy effective prior to chemotherapy: MD Anderson Phase II study suggests patients with lymphoma subtype may be able to avoid chemotherapy in the future

Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5 percent complete response rate (CRR) when given prior to any chemotherapy…

Bone cells suppress cancer metastases

In breast cancer, there are cases of women and men whose cancer returns in their bones 20-30 years after they were treated for their primary disease and thought they were cancer-free. This phenomenon always puzzled Jefferson researcher Karen Bussard, PhD. How is it possible that breast cancer cells from a…

Tumor mutations may predict response to immunotherapy

Checkpoint inhibitor drugs that stimulate the immune system have become a growing success story in the treatment of some cancers. But about half of patients whose tumors are marked by a large number of mutations from so-called mismatch repair genetic deficiency fail to respond to the drugs. Now, researchers from…

Multiple myeloma: DNA rearrangement may predict poor outcomes

A certain type of DNA marker predicts poor outcomes in multiple myeloma, researchers at Winship Cancer Institute, Emory University have found. The marker is a kind of rearrangement of chromosomes that is rarely tested for, but may indicate resistance to immunomodulatory drugs such as lenalidomide, which have become standard therapies…